Dr. Vincent Dion awarded $250,000 grant to pursue gene editing technology development to find a cure for DM.
The Myotonic Dystrophy Clinical Research Network (DMCRN) sites are currently conducting a critically-important research study designed to help drug developers successfully design clinical trials and understand how to assess the efficacy of potential therapies.
MDF designed this volunteer initiative to educate the next generation of medical professionals about myotonic dystrophy in order to improve clinical care and shorten the diagnostic odyssey. We need you!
Disorders of sleep and breathing are well characterized for DM1, but what about DM2?
A new review looks at the opportunities and hurdles for genome editing in neuromuscular disease.
Respiratory dysfunction in DM1 draws new attention.
Daily activities and social participation are assessed in a longitudinal study of DM1.
Dr. Melissa Dixon at the University of Utah Department of Pediatrics is conducting a study to learn more about how congenital myotonic dystrophy (CDM) and childhood-onset myotonic dystrophy affect thinking, memory, attention, brain function, and how these processes change over time.
- 1 of 44
- next ›